ArticleNature communications2023
Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 35 citations in OpenAlex.
- Glycan-binding properties of SARS-CoV-2 spike proteins: interactions with aminoglycoside antibiotics.Scientific reports · 2026Article
- Perspective Overview of Changing Population Immunity to COVID-19 in the Context of Infection, Vaccination, and Emerging SARS-CoV-2 Variants.Pathogens (Basel, Switzerland) · 2025Review
- Breathless Aftermath: Post-COVID-19 Pulmonary Fibrosis.Viruses · 2025Review
- Critical amino acid residues in human ACE2 for SARS-CoV-2 spike protein binding and virus entry.Microbiology spectrum · 2025Article
- Viral sepsis-induced mortality of older patients infected by the Omicron subvariant BA.5 of SARS-CoV-2: a retrospective study.BMC infectious diseases · 2025Article
- Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineage.Nature communications · 2024Article
- Computationally designed Spike antigens induce neutralising responses against the breadth of SARS-COV-2 variants.NPJ vaccines · 2024Article
- BA.5 sub-lineages associated with higher severity of COVID-19 infection: A cross-sectional study in Indonesia.IJID regions · 2024Article
- Genomic Surveillance and Mutation Analysis of SARS-CoV-2 Variants among Patients in Saudi Arabia.Microorganisms · 2024Article
- Diversity of Omicron sublineages and clinical characteristics in hospitalized patients in the southernmost state of Brazil.BMC infectious diseases · 2024Article
- SARS-CoV-2 Omicron (BA.4, BA.5) variant: Lessons learned from a new variant during the COVID-19 pandemic.Health science reports · 2024Article
- Characteristics of patients with non-severe infections of different SARS-CoV-2 omicron subvariants in China.Frontiers in medicine · 2024Article
- Multi-epitope vaccine against SARS-CoV-2 targeting the spike RBD: an immunoinformatics approach.Future science OA · 2024Article
- Reinfection rate and disease severity of the BA.5 Omicron SARS-CoV-2 lineage compared to previously circulating variants of concern in the Canary Islands (Spain).Emerging microbes & infections · 2023Observational
- Protective effect of previous infection and vaccination against reinfection with BA.5 Omicron subvariant: a nationwide population-based study in Japan.The Lancet regional health. Western Pacific · 2023Article
- Overview of immunological & virological factors driving the evolution & global spread of SARS-CoV-2 variants.The Indian journal of medical research · 2023Review
- Risk of severe outcomes among SARS-CoV-2 Omicron BA.4 and BA.5 cases compared to BA.2 cases in England.The Journal of infection · 2023Article
- Increased vaccine sensitivity of an emerging SARS-CoV-2 variant.Nature communications · 2023Article
- Human airway and nasal organoids reveal escalating replicative fitness of SARS-CoV-2 emerging variants.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Trends in Cases, Hospitalizations, and Mortality Related to the Omicron BA.4/BA.5 Subvariants in South Africa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Expansion of the SARS-CoV-2 BA.4 and BA.5 Omicron subvariants in populations with prevalent immunity from prior infection and vaccination, and associated burden of severe COVID-19, has raised concerns about epidemiologic characteristics of these lineages including their association with immune escape or severe clinical outcomes. Here we show that BA.4/BA.5 cases in a large US healthcare system had at least 55% (95% confidence interval: 43-69%) higher adjusted odds of prior documented infection than time-matched BA.2 cases, as well as 15% (9-21%) and 38% (27-49%) higher adjusted odds of having received 3 and ≥4 COVID-19 vaccine doses, respectively. However, after adjusting for differences in epidemiologic characteristics among cases with each lineage, BA.4/BA.5 infection was not associated with differential risk of emergency department presentation, hospital admission, or intensive care unit admission following an initial outpatient diagnosis. This finding held in sensitivity analyses correcting for potential exposure misclassification resulting from unascertained prior infections. Our results demonstrate that the reduced severity associated with prior (BA.1 and BA.2) Omicron lineages, relative to the Delta variant, has persisted with BA.4/BA.5, despite the association of BA.4/BA.5 with increased risk of breakthrough infection among previously vaccinated or infected individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.